News & Updates

Interim results of the Italian, multicentre, open-label, phase IIIb MAURIS trial in “real-world” patients with untreated extensive-stage small-cell lung cancer (ES-SCLC) show similar safety and efficacy to those achieved by atezolizumab plus carboplatin and etoposide in the pivotal, phase I/III IMpower133 trial.

Prophylactic interferon-alpha (IFN-α) administered intranasally slashed the incidence of COVID-19 by almost half in a cohort of cancer patients in the C-SMART study.

The National Lung Screening Trial (NLST) in Singapore falls short of identifying some individuals, particularly women, who are at an increased risk of developing lung cancer, according to a study. However, those who meet the criteria may derive significant benefits from the screening.